This Article Figures Only Full Text Full Text (PDF) Online Appendix View Related Keeping an Eye on Imaging on CVN View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Higo, T. Articles by Kodama, K. Search for Related Content PubMed Articles by Higo, T. Articles by Kodama, K. Related Collections Related Article

Atherosclerotic and Thrombogenic Neointima Formed Over Sirolimus Drug-Eluting Stent

An Angioscopic Study

Cardiovascular Division, Osaka Police Hospital, Osaka, Japan

^_* Reprint requests and correspondence: Dr. Yasunori Ueda, Cardiovascular Division, Osaka Police Hospital, 10-31 Kitayama-cho, Tennoji-ku, Osaka 543-0035, Japan (Email: ueda{at}oph.gr.jp).

Objectives: We sought to examine by angioscopy the neointima formation and thrombogenic potential of the neointima after deployment of a drug-eluting stent (DES).

Background: Late stent thrombosis after DES implantation, a major safety concern, has been associated with poor strut coverage by neointima. Intracoronary angioscopy provides a method for visual evaluation of stent coverage by neointima and detection of thrombus in the stented coronary segment.

Methods: Patients undergoing implantation of a sirolimus DES (n = 57) were serially examined by angioscopy immediately after (baseline) and again at 10 months (follow-up) after implantation. The angioscopic color grade of the neointima from white to yellow was assessed in a semiquantitative manner. Stent coverage was classified into not covered (Grade 0), covered by a thin layer (Grade 1), or buried under neointima (Grade 2). The thrombogenic potential of the neointima was evaluated by the prevalence of thrombus on the neointima.

Results: The maximum yellow color grade of the neointima within DES-implanted lesions increased significantly from baseline to follow-up (1.4 ± 1.1 vs. 1.9 ± 0.6, p = 0.0008). Even among lesions without yellow color at baseline, yellow color was detected in 94% (17 of 18) of lesions at follow-up. The prevalence of thrombus was significantly higher on the yellow than on the white neointimal areas. Thrombus was detected on yellow and/or Grade-0/1 neointima, but never on the white Grade-2 neointima.

Conclusions: Sirolimus DES promoted formation of atherosclerotic yellow neointima in the stent-implanted lesion at 10-month follow-up. Thrombus was detected more often on the yellow area than on the white area and was never detected where a stent was buried under white neointima. These data suggest that the increased potential risk of late stent thrombosis in DES lesions may be due to the newly formed yellow neotima and cholesterol-laden plaque.

Key Words: drug-eluting stent • neointima • yellow neointima • thrombus

Abbreviations and Acronyms   ACS = acute coronary syndrome   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   PCI = percutaneous coronary intervention

Related Article

One Step Forward and Two Steps Back With Drug-Eluting-Stents: From Preventing Restenosis to Causing Late Thrombosis and Nouveau Atherosclerosis

Gaku Nakazawa, Marc Vorpahl, Aloke V. Finn, Jagat Narula, and Renu Virmani
J. Am. Coll. Cardiol. Img. 2009 2: 625-628. [Full Text] [PDF]

This article has been cited by other articles:

				G. Nakazawa, M. Vorpahl, A. V. Finn, J. Narula, and R. Virmani One step forward and two steps back with drug-eluting-stents from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 625 - 628. [Full Text] [PDF]

				Y. Chandrashekhar, M. J. Kern, and J. Narula Devices, biology, imaging, and the regulatory processes... J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 670 - 673. [Full Text] [PDF]